C7orf25

Across TCGA pan-cancer cohorts, C7orf25 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated C7orf25 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher C7orf25 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated C7orf25 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

LUAD, UCEC, and GBM are the cancer types where C7orf25 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.848	0.965	<.001	88	view →
UCEC	OS	Median	II,III,IV	0.620	1.000	.011	10	view →
GBM	DFS	Median	All	0.837	0.668	.006	6	view →
PDAC	DFS	Quartile	III,IV	0.834	0.316	.013	2	view →
HNSC	OS	Median	III,IV	0.783	0.930	.044	1	view →
LSCC	OS	Median	II,III,IV	0.695	0.857	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

C7orf25–LUAD (DFS)

Open the LUAD breakdown →